ARMO BioSciences *

ARMO BioSciences was a clinical-stage immuno-oncology biopharmaceutical company based in Redwood City, California, developing biologic therapeutics that activate a patient's own immune system to fight cancer. Its lead candidate was pegilodecakin (AM0010), a PEGylated recombinant human interleukin-10 (IL-10) evaluated across solid tumors. Backed by GV and Kleiner Perkins, the company IPO'd on NASDAQ in 2018 and was acquired by Eli Lilly and Company that same year for approximately $1.6 billion; its former web domain now redirects to lilly.com. As a life-sciences therapeutics developer it exposes no public developer API, SDK, or documentation surface. This profile is retained in the API Evangelist network as a portfolio/acquisition record rather than an active API provider.

ARMO BioSciences * is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Immuno-Oncology, and Pharmaceuticals.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyLife SciencesBiotechnologyImmuno-OncologyPharmaceuticalsCancerTherapeuticsAcquired

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/armo-biosciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: armo-biosciences
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/armo-biosciences.png
name: ARMO BioSciences *
description: ARMO BioSciences was a clinical-stage immuno-oncology biopharmaceutical company based in Redwood City, California,
  developing biologic therapeutics that activate a patient's own immune system to fight cancer. Its lead candidate was pegilodecakin
  (AM0010), a PEGylated recombinant human interleukin-10 (IL-10) evaluated across solid tumors. Backed by GV and Kleiner Perkins,
  the company IPO'd on NASDAQ in 2018 and was acquired by Eli Lilly and Company that same year for approximately $1.6 billion;
  its former web domain now redirects to lilly.com. As a life-sciences therapeutics developer it exposes no public developer
  API, SDK, or documentation surface. This profile is retained in the API Evangelist network as a portfolio/acquisition record
  rather than an active API provider.
url: https://raw.githubusercontent.com/api-evangelist/armo-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
- kleiner-perkins
x-acquired-by: eli-lilly
x-acquired-year: '2018'
x-status: acquired
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Life Sciences
- Biotechnology
- Immuno-Oncology
- Pharmaceuticals
- Cancer
- Therapeutics
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence